CVS Predicts an Ugly 2019 After Closing $68 Billion Aetna Deal

  • Shares fall 9.4 percent as CEO calls 2019 ‘transition year’
  • Company takes new $2.2 billion writedown on 2015 Omnicare deal
CVS Shares Slump as Omnicare Deal Hits 2019 Forecast
Lock
This article is for subscribers only.

CVS Health Corp. said its results this year will be dragged down by rising costs and poor results from a 2015 takeover of nursing-home pharmacy Omnicare, raising questions about whether an ambitious $68 billion purchase of insurer Aetna last year was the right move for the health-care giant.

Just as it works to integrate one of the most ambitious deals in the health-care industry, CVS is being beset by bad news from all sides. A struggling nursing-home industry has created fewer customers for Omnicare, leading to $6.1 billion in writedowns. Higher wages and employee benefits cut into the gains from the 2017 corporate tax overhaul. And one of CVS’s main businesses, pharmacy-benefit management services for insurers and employers, is under attack in Washington.